Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

J&J To Pay $572M In Opioid Case; Plus Case-Shiller Home Price Read

Published 08/26/2019, 10:24 PM
Updated 07/09/2023, 06:31 AM

Tuesday, August 27, 2019

Again, here at the end of August, we mostly wait for a time of more populous economic data; in a week, we’ll start seeing things like new jobs reports from the month of August. Until then, we sift through tea leaves until we can land on something new and concrete…

Which brings us to Norman, Oklahoma, where Johnson & Johnson (NYSE:JNJ) has been ruled against in a major opioid epidemic landmark case. The pharma giant now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use beyond responsible levels. The other two companies originally named in the case — Teva (NYSE:TEVA) and Purdue Pharma — had already settled for $85 million and $270 million, respectively.

However, shares are up roughly 1% in today’s pre-market for J&J, as analysts following the trial and other newsworthy items amid the U.S. opioid epidemic expected as much as a $17 billion charge to J&J in the case. Wall Street had priced in $1-2 billion. So even though J&J has been ruled to pay more than double Purdue’s settlement — J&J will no doubt be appealing this ruling — the dollar amount is still well below what many investors were fearing.

Not only J&J, but other pharma companies that provide opiates for patients — Teva, Mallinckrodt (NYSE:MNK) , Endo International (NASDAQ:ENDP) — are all up 3% in today’s pre-market. That said, the Oklahoma case is but the tip of the iceberg; analysts now look toward a new trial in Ohio this October on opioid abuse and pharma companies’ involvement in it. For that case, J&J is already openly discussing settlement options.

Case-Shiller Home Prices Up, but Slower

The late read (from June) — but deemed most accurate — on U.S. home prices from the latest Case-Shiller index showed home prices continuing to rise, but lower than in recent months. A headline of +3.1% annually is 20 basis points lower than the read for May. The 10-City index rose 1.8% while the 20-City was +2.1%, both down from the 2.2% and 2.4% in the previous month, respectively).

Leading cities were some of the usual suspects: Phoenix led the way in June home pricing, +5.8%, followed by Las Vegas at 5.5% and Tampa at 4.7%. Analysts cite hopefulness for future reads, with lower mortgage rates hopefully having spurred home prices in the later summer months. But, of course, we will need to wait a while to see if these expectations will have come to fruition.

Mark Vickery
Senior Editor

Questions or comments about this article and/or its author? Click here>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Johnson & Johnson (JNJ): Free Stock Analysis Report

Endo International plc (ENDP): Free Stock Analysis Report

Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report

Mallinckrodt public limited company (MNK): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.